Announcements Trials
Browse Landscape

Phase

Phase 2 29Phase NA 20Phase 1 13Phase EARLY_PHASE1 9Phase 1/2 3Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Thyroid Neoplasms 1Lymphoma 1Lung Neoplasms 1Colorectal Neoplasms 1Brain Neoplasms 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20venetoclax 18Vincristine 18apatinib 17Trastuzumab 17Rituximab 17Prednisone 17Letrozole 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole × Clear all
NCT00123760 2016-02-25

Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer

AHS Cancer Control Alberta

Phase 2/3 Completed
10,838 enrolled
CNSGastrointestinalHead & NeckLymphoidThoracic

Brain Neoplasms, Lung Neoplasms, Lymphoma, Thyroid Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡